<SEC-DOCUMENT>0001213900-14-004911.txt : 20140716
<SEC-HEADER>0001213900-14-004911.hdr.sgml : 20140716
<ACCEPTANCE-DATETIME>20140716080051
ACCESSION NUMBER:		0001213900-14-004911
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20140716
ITEM INFORMATION:		Regulation FD Disclosure
FILED AS OF DATE:		20140716
DATE AS OF CHANGE:		20140716

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUCELL CORP /DE/
		CENTRAL INDEX KEY:			0000811641
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				010382980
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12934
		FILM NUMBER:		14977054

	BUSINESS ADDRESS:	
		STREET 1:		56 EVERGREEN DR
		CITY:			PORTLAND
		STATE:			ME
		ZIP:			04103
		BUSINESS PHONE:		2078782770

	MAIL ADDRESS:	
		STREET 1:		56 EVERGREEN DRIVE
		CITY:			PORTLAND
		STATE:			ME
		ZIP:			04103
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f8k071614_immucell.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 2.5pt; border-top: Black 2pt solid; border-bottom: Black 0.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%"><tr><td style="padding: 2.25pt"><P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><BR>
                                         <FONT STYLE="font-size: 10pt"><B>UNITED STATES</B><BR>
                                         <B>SECURITIES AND EXCHANGE COMMISSION</B><BR>
                                         Washington, D.C. 20549</FONT></P>



        <P STYLE="font: 12pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0"><FONT STYLE="font-size: 10pt"><B>FORM
        8-K </B></FONT></P>
        <P STYLE="font: 12pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0"><FONT STYLE="font-size: 10pt"><B>CURRENT
        REPORT </B></FONT></P>
        <P STYLE="font: 12pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0"><FONT STYLE="font-size: 10pt"><B>Pursuant
        to Section 13 or 15(d) of the</B><BR>
        <B>Securities Exchange Act of 1934 </B></FONT></P></TD></TR></TABLE>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<tr>
    <td colspan="3" style="padding-bottom: 12pt; font: 12pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt"><B>Date
    of Report: July 16, 2014</B><br>
    (Date of earliest event reported)</FONT></td></tr>
<tr>
    <td colspan="3" style="font: 12pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt"><B>ImmuCell
    Corporation</B><br>
    (Exact name of registrant as specified in its charter)</FONT></td></tr>
</TABLE>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<tr>
    <TD COLSPAN="5" STYLE="font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
<TR>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>DE</B></FONT><BR>
    <FONT STYLE="font-size: 10pt">(State or other jurisdiction of incorporation)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt"><B>001-12934</B><BR>
    (Commission File Number)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt"><B>01-0382980</B></FONT><BR>
    <FONT STYLE="font-size: 10pt">(IRS Employer Identification Number)</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
<tr>
    <TD><P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>56
        Evergreen Drive</B></FONT></P>
        <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Portland,
        Maine </B><br>
        (Address of principal executive offices)</FONT></P></td>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt"><B>04103</B><br>
    (Zip Code)</FONT></td></tr>
</TABLE>

<P STYLE="margin: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<tr>
    <TD COLSPAN="5" STYLE="font: 12pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt"><br>
    <B>207-878-2770</B><br>
    (Registrant's telephone number, including area code)</FONT></td></tr>
<tr>
    <TD COLSPAN="5" STYLE="font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
<tr>
    <TD COLSPAN="5" STYLE="font: 12pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt"><B>Not
    Applicable</B><br>
    (Former Name or Former Address, if changed since last report)</FONT></td></tr>
</table>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><BR>
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant
under any of the following provisions:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font: 10pt Wingdings">o</FONT><FONT STYLE="font-size: 10pt">
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font: 10pt Wingdings">o</FONT><FONT STYLE="font-size: 10pt">
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font: 10pt Wingdings">o</FONT><FONT STYLE="font-size: 10pt">
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font: 10pt Wingdings">o</FONT><FONT STYLE="font-size: 10pt">
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B>Item 7.01 Regulation FD Disclosure</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">The Company has recently engaged
an investor relations firm to introduce the Company more broadly to the investment community. In response to inquiries for more
detailed information about the potential market for the Company&rsquo;s products, <B>First Defense<SUP>&reg;</SUP></B> and <B>Mast
Out<SUP>&reg;</SUP></B>, the Company is furnishing this public disclosure in accordance with Regulation FD and under the forward-looking
statement disclaimer provided at the end of this document.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B>First Defense<SUP>&reg;</SUP>:</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B>First Defense<SUP>&reg; </SUP></B>is
derived from bovine colostrum and is delivered orally immediately after birth with USDA-approved claims to protect the newborn
calves from scours (bovine enteritis or diarrhea) caused by <I>E. coli</I> and coronavirus. Based on the Company&rsquo;s internal
best estimates and calculations and some available published literature, it is the Company&rsquo;s opinion that scours causes
approximately $761,000,000 in economic losses (primarily related to deaths, treatments and reduced productivity) to the U.S. dairy
and beef calf industries annually.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B>First Defense<SUP>&reg; </SUP></B>competes
primarily with two products on the market today, Calf-Guard (Zoetis) and Bovine Ecolizer and Bovine Ecolizer +C (Novartis). There
are other products and methods to reduce losses due to scours, but the Company&rsquo;s sales team focuses directly on these two
competitive products which together with <B>First Defense<SUP>&reg; </SUP></B>are used to treat approximately 3.0 million calves
per year. This estimate represents approximately 8% of the 37,054,000 calves born alive each year. Approximately 8,500,000 calves
per year are diagnosed with scours, representing approximately 23% of all live births. This segment has been growing in recent
years by 3-5% and <B>First Defense<SUP>&reg; </SUP></B>has consistently grown its share of market in the segment with an estimated
25% market share in 2013 up from 22% in 2012. First half 2014 results continue to show strengthening performance as <B>First Defense<SUP>&reg;
</SUP></B>is projected to attain ~ 28% share of market based on internal estimates. We believe that there is an opportunity for
growth in this product category as progressive producers adopt proactive preventative protocols over a treatment mentality. This
information is approximated but does give the investor some indication of the market potential for <B>First Defense<SUP>&reg;</SUP></B>.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B>Mast Out<SUP>&reg;</SUP>:</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B>Mast Out<SUP>&reg;</SUP></B> is
a Nisin-based treatment for subclinical mastitis in lactating dairy cows, subject to FDA approval. It is widely understood that
mastitis is the largest cause of economic harm to the U.S. dairy industry, estimated at approximately $2,000,000,000 per year.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">It is very difficult to accurately assess the market potential for this product
because currently subclinical mastitis is generally not treated due to the cost of discarded milk, which is required with the
use of all traditional antibiotic treatments. With a zero milk discard claim in the U.S. market, the Company expects to revolutionize
current mastitis treatment practices by making the treatment of subclinical infection economical. Over the past two to three years,
the Company has examined many different sales models and discussed the market potential for this product with several potential
marketing partners. By our best estimate, we project potential retail sales for</FONT></P>



<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B>Mast Out<SUP>&reg;</SUP></B> of
approximately $5,400,000 during the first year after market launch and approximately $31,700,000 during the tenth year after market
launch. The actual sales level achieved could be significantly higher or lower depending on many different variables. The critical
assumptions underlying these estimates are as follows:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"># of U.S. cows in lactation: 7,868,000</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">Projected % of cows treated with
<B>Mast Out<SUP>&reg;</SUP></B> over first ten years after market launch: 0.40% during first quarter after market launch to 3.37%
during 40<SUP>th</SUP> quarter after market launch.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">Each cow has four quarters (teats)
per udder. Some cows are infected in more than one quarter. The average number of quarters treated with <B>Mast Out<SUP>&reg;
</SUP></B>per cow: 1.15</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"># of <B>Mast Out<SUP>&reg;</SUP></B>
doses per treatment: three</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">Suggested retail price per dose:
$8.99</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">This data was derived from our best
interpretation of industry reports and our own understandings and projections.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">Forward-looking statement disclaimer:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><I>This presentation contains &quot;forward-looking
statements&quot; within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act
of 1934. Such statements include, but are not limited to, any statements relating to: projections of future financial performance;
the scope and timing of future product development work and commercialization of our products; the outcome of pending or anticipated
applications for future regulatory approvals; factors that may affect the dairy and beef industries and future demand for our
products; anticipated competitive and market conditions; and any other statements that are not historical facts. Forward-looking
statements can be identified by the use of words such as &quot;expects&quot;, &quot;may&quot;, &ldquo;hopes&rdquo;, &quot;anticipates&quot;,
&quot;aims&quot;, &quot;intends&quot;, &quot;would&quot;, &quot;could&quot;, &quot;should&quot;, &quot;will&quot;, &quot;plans&quot;,
&quot;believes&quot;, &quot;estimates&quot;, &quot;targets&quot;, &quot;projects&quot;, &quot;forecasts&quot; and similar words
and expressions. In addition, there can be no assurance that future developments affecting us will be those that we anticipate.
Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties
or delays in development, testing, regulatory approval, production and marketing of our products, competition within our anticipated
product markets, the uncertainties associated with product development, pharmaceutical-grade Nisin manufacturing, our potential
reliance upon third parties for financial support, products and services, changes in laws and regulations, decision making by
regulatory authorities and other risks detailed from time to time in filings we make with the Securities and Exchange Commission,
including our Quarterly Reports on Form 10-Q, our Annual Reports on Form 10-K and our Current Reports on Form 8-K. Such statements
are based on our current expectations, but actual results may differ materially due to various factors.</I></FONT></P>



<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 6pt"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 6pt">&nbsp;<B>SIGNATURE&nbsp;</B></P>

<P STYLE="margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0; text-indent: 0.5in">Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="margin: 0; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0; margin-top: 0pt; margin-bottom: 6pt"></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Dated: July 16, 2014</FONT></TD>
    <TD COLSPAN="2"><B><FONT STYLE="font-size: 10pt">IMMUCELL CORPORATION</FONT></B></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 66%">&nbsp;</TD>
    <TD STYLE="width: 4%">By:&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 30%">/s/Michael F Brigham</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-top: #000000 1px solid">Michael F. Brigham<BR><I>President, Chief Executive Officer</I><BR>
        <I>and Principal Financial Officer</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt">&nbsp;</P>

<HR NOSHADE SIZE="2" STYLE="color: Black; width: 100%; margin-top: 3pt; margin-bottom: 3pt">
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt"><br>
&nbsp; &nbsp;</P>




<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
